ZONEGRAN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZONEGRAN (ZONEGRAN).
Anticonvulsant; blocks voltage-gated sodium and calcium channels, enhances GABA-mediated inhibition, and inhibits glutamate release.
| Metabolism | Primarily metabolized via hepatic glucuronidation and acetylation; CYP3A4 partially involved. |
| Excretion | Renal: approximately 62% of the dose as unchanged drug and metabolites (primarily glucuronide conjugates and N-acetylzonisamide). Fecal: approximately 16% (including metabolites). Biliary excretion is minimal. Total recovery in urine and feces accounts for ~80% of the dose. |
| Half-life | Terminal elimination half-life is approximately 63 hours (range 50-70 hours) in adults. The long half-life allows for once- or twice-daily dosing. Steady state is reached after about 2 weeks of repeated dosing. |
| Protein binding | Approximately 40-60% bound to plasma proteins, primarily albumin. Binding is not affected by drug concentration in the therapeutic range. |
| Volume of Distribution | Approximately 0.8-1.6 L/kg, indicating extensive distribution into tissues (total body water). The apparent volume of distribution is large, suggesting accumulation in tissues such as red blood cells (zonisamide concentrates in RBCs with a RBC:plasma ratio of about 8:1). |
| Bioavailability | Oral: Approximately 100% (well absorbed). The absolute bioavailability is near complete with no significant first-pass effect. Food does not affect the extent of absorption but may delay the rate. |
| Onset of Action | Oral: Clinical effect (seizure reduction) may be observed within 1-2 weeks, but full therapeutic effect may require up to 4-6 weeks due to slow titration and time to steady state. |
| Duration of Action | Duration of antiepileptic effect is approximately 24 hours with once-daily dosing, owing to the long half-life. Steady-state concentrations are maintained with regular dosing. |
| Molecular Weight | 212.23 |
| Action Class | Brain carbonic anhydrase inhibitors |
Initial: 100 mg orally once daily for 2 weeks, then may increase by 100 mg/day at 2-week intervals; usual maintenance: 200-400 mg/day divided once or twice daily; maximum: 600 mg/day.
| Dosage form | CAPSULE |
| Renal impairment | CrCl >= 50 mL/min: no adjustment; CrCl 20-49 mL/min: reduce dose by 50%; CrCl < 20 mL/min: avoid use; hemodialysis: administer 50% of usual dose after dialysis. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: use with caution, reduce dose by 50%; Child-Pugh Class C: contraindicated. |
| Pediatric use | Age >= 6 years: initial 1 mg/kg/day once daily for 2 weeks, then increase by 1 mg/kg/day at 2-week intervals; usual maintenance 2-3 mg/kg/day; maximum 6 mg/kg/day or 400 mg/day. |
| Geriatric use | Start at lower initial dose (50-100 mg/day) due to reduced renal function; titrate slowly; monitor for cognitive impairment and electrolyte disturbances. |
| 1st trimester | Associated with increased risk of major congenital malformations, including neural tube defects, cleft lip/palate, and cardiac defects. Use only if benefit outweighs risk. |
| 2nd trimester | May cause fetal growth restriction and low birth weight. Monitor fetal growth closely. |
| 3rd trimester | Neonatal withdrawal syndrome (irritability, jitteriness) reported. Administer lowest effective dose and monitor neonate. |
Clinical note
Comprehensive clinical and safety monograph for ZONEGRAN (ZONEGRAN).
| Placental transfer | Crosses the placenta readily; cord/maternal ratio ~0.8-1.0. Detected in fetal tissues. |
| Breastfeeding | Zonegran is excreted in breast milk. Infant serum levels can reach up to 1.6 mcg/mL. Monitor infant for drowsiness, poor feeding, and diarrhea. Use caution, especially in neonates or preterm infants. |
■ FDA Black Box Warning
Serious skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN); risk of oligohidrosis and hyperthermia in pediatric patients.
| Serious Effects |
Hypersensitivity to zonisamide or sulfonamidesConcomitant use with other carbonic anhydrase inhibitors (e.g., acetazolamide) due to increased risk of metabolic acidosis
| Precautions | Serious skin reactions (SJS/TEN); oligohidrosis and hyperthermia in children; acute myopia and secondary angle-closure glaucoma; depression and suicidal behavior; abrupt withdrawal may precipitate seizures; renal impairment may require dose adjustment. |
| Food/Dietary | No significant food interactions. Avoid excessive intake of high-sodium or high-calcium foods as these may influence kidney stone risk. Do not take with carbonic anhydrase inhibitors like acetazolamide due to additive acidosis risk. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy Category D. Zonegran (zonisamide) is associated with an increased risk of major congenital malformations, particularly neural tube defects, when used during the first trimester. Exposure in the second and third trimesters may cause fetal hydantoin syndrome, growth retardation, and developmental delay. Risk of malformations is dose-dependent and increases with polytherapy. |
| Fetal Monitoring | Monitor zonisamide serum concentrations throughout pregnancy; target trough levels based on individual response. Perform regular fetal ultrasonography (including high-resolution anatomy scan at 18-20 weeks) to detect neural tube defects. Assess for maternal metabolic acidosis, renal function, and liver function. Monitor for signs of fetal distress and growth restriction via serial growth scans in third trimester. |
| Fertility Effects | In reproductive studies, zonisamide caused increased embryo-fetal death and skeletal anomalies. Human data on fertility are limited; however, zonisamide may impair spermatogenesis in males and cause menstrual irregularities or ovulatory dysfunction in females due to potential hormonal interactions. |
| Clinical Pearls | Zonegran (zonisamide) is a sulfonamide anticonvulsant; assess for sulfa allergy. Monitor renal function as dose adjustment needed in renal impairment. Can cause metabolic acidosis via carbonic anhydrase inhibition; check baseline and periodic serum bicarbonate. Weight loss is common; monitor in pediatric patients. Titrate slowly to reduce CNS side effects. Avoid use in patients with nephrolithiasis due to increased risk of calcium phosphate stones. |
| Patient Advice | Take with or without food; swallow capsules whole, do not crush or chew. · Avoid alcohol as it may increase drowsiness and dizziness. · Report rash, fever, or swollen lymph nodes immediately as signs of hypersensitivity. · Watch for signs of metabolic acidosis: rapid breathing, fatigue, confusion, or irregular heartbeat. · May cause drowsiness, dizziness, or blurred vision; avoid driving until effects are known. · Drink adequate fluids to reduce kidney stone risk; report pain during urination. · Do not stop abruptly as withdrawal may increase seizure frequency. |